Reported from ACC 2023 / WCC

Edoardo Zancanaro provides his take on this clinical trial presented by Enoch Akowuah at the American College of Cardiology Scientific Session (ACC.23/WCC).

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Nicola Ryan provides her take on the final results of OPT-BIRISK which were presented by Yaling Han during the ESC 2023 congress in Amsterdam.

Note the assumptions in this article are based on the presentation alone as the trial has not yet been published.

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.

Make the most of the insights from Jacob Thomsen Loenborg’s interview with Chiara De Biase and Ali Nazmi Calik’s article to capture the key takeaways from this trial, simultaneously published in the NEJM, presented at the ESC Congress 2024 in London.

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Nicola Ryan provides her take on the 10-year follow-up of the HOST-EXAM, which was presented by Hyo-Soo Kim at ACC.26 in New Orleans.

Vijay Kunadian summarizes the key points of the LBT session of the ESC congress 2021 held on Sunday, 29 August focusing on the Lancet Commission to reduce the global burden of heart disease in women by 2030.

Paris, France. 19 May 2022. We CARE, a joint initiative of PCR and Stent – Save a Life!, dedicated to restoring faith in cardiovascular healthcare and increasing awareness of the importance of timely and accessible treatment, is presenting a first study at EuroPCR 2022: a UK...

Mirvat Alasnag provides her take on the Altshock-2 randomized clinical trial which was presented by Alice Sacco at ACC.25 in Chicago.

Analyze this EIJ image to see how surgical aortic bioprostheses with expandable ring technology can significantly enhance future ViV procedures.

Ali Nazmi Calik provides his take on the results of the PREVENT trial presented at ACC.24 in Atlanta.

Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.

BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...

This is a 44-year old male patient with an aortic root fistula to the right heart after past infective aortic valve endocarditis. Interventional shunt occlusion was successfully performed using a transcatheter closure device.

TCT 2021: Radoslaw Parma reviews the CHOICE-CLOSURE multicentre, randomized, controlled, open-label clinical trial presented by Mohamed Abdel-Wahab. The study compared outcomes of percutaneous femoral artery closure using a plug-based and a primary suture-based strategy in patients undergoing TAVI.

Paris, France. Since the start of the COVID-19 pandemic, patients have been consistently deprived of timely cardiovascular treatment. This is due in part to measures taken in response to the sanitary crisis, but it is also due to patients' own unwillingness to seek medical help, even...

Examination of the study methodology and results according to the PICOT principle, SWOT analysis and real-world applicability

Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...